X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. It is under phase 3 clinical trials for the treatment of acute ST-elevation myocardial infarction (STEMI).
Lead Product(s): Sodium Iodide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: FDY-5301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. Sodium iodide has been observed to have various physiological effects on the body, including on the heart.
Lead Product(s): Sodium Iodide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: FDY-5301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
Phase 1 data have demonstrated no signs of toxicity in healthy subjects, and a Phase 2 study suggested a reduction in infarct size and improved cardiac function in patients treated with FDY-5301 after suffering an acute myocardial infarction (AMI).
Lead Product(s): Sodium Iodide
Therapeutic Area: Musculoskeletal Product Name: FDY-5301
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
